Viking Therapeutics Inc. (NASDAQ:VKTX)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
VKTX Weekly Chart

Old Forum Content for VKTX

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • Dig44north: @woodman $LLY they’re still rumoured to be looking at $VKTX
  • woodman: @Dig44north $LLY $VKTX - Yeah those rumors have been around for a long time it seems. More like hopes, lol. I suspect $GPCR is being looked at too. Lots of potential targets in the obesity space.
  • woodman: @Dig44north $LLY $VKTX - Keep an eye on $ALT (no position currently) in the space. Long $LLY (as of today thx to you) $VKTX $GPCR (stopped out yesterday but bought back) and $GUTS
  • billyzeke: $VKTX is showing some spunk right now, I took some around $38- may just be a trade for me, TBD by the close. #EDIT -meant to say day trade
  • woodman: @billyzeke $VKTX #EDIT - I'm holding a $VKTX position. The coming FDA end of Phase 2 meeting (oral VK2735) should be intereting, though hard to say whether FDA will permit it to go straight to Phase 3 without a Phase 2b.
  • DavidK: @woodman $VKTX #EDIT $WVE - read the news . Of it works , these other players are gonna be in trouble
  • billyzeke: @woodman $VKTX #EDIT That dropped fast I sold half at 39 and had to dump the opther half quick, out of it @ 38.28.
  • woodman: @DavidK $VKTX $WVE #EDIT - Check out $GUTS, too.
  • billyzeke: @woodman $VKTX #EDIT I got a nice day-trade on it on Thursday after I saw your post, many thanks for the heads up! #EDIT Thursday not Monday... geez my brain is fried today. lol
  • Geewhiz: @woodman $VKTX $WVE $GUTS #EDIT Checking entrails an interesting way to trade. ;-)
  • woodman: @DavidK $VKTX $WVE #EDIT - Very early trial. No real insight into safety at this juncture. So yes, interesting, but miles to go. It will be a long ride from here. Also, it announced a $250 million offering on the news.
  • woodman: $VKTX is in an interesting operational spot. They have an end of Phase 2 meeting coming up with the FDA. This is for its oral iteration of its obesity med VK2735 (they have a injectible version, too). The company wants to move straight to Phase 3 wi ...
  • joelsg1: @woodman $VKTX Compelling. I've still got $GPCR but yours is better.
  • woodman: @joelsg1 $VKTX $GPCR - I have some $GPCR too, because I think big pharma is looking to acquire obesity drug assets and I suspect GPCR (2B market cap) is in the mix for that. VKTX is at $4.4B, but a lot of big investors are in at $85/share when it did that raise in early 2024. That's more than double current share price, and it's hard to imagine $VKTX accepting an acquistion price without a premium on top of that. The good thing is that VKTX still has a ton of cash from that raise, and a move right to Phase 3 for oral would save them much of that cash.
  • traderbren: $VKTX - seeing some interest -- and working on clearing the 20d
  • woodman: @traderbren $VKTX - Ha, I was just about to post on it.
  • woodman: $ABBV $VKTX $GPCR - ABBV's CEO, CFO, and CMO have been making comments at investor conferences about their interest in the obesity therapeutic area - which they regard as a growth area - with the CFO (who is the most conservative on the management team) saying they are still looking into assets in this area, and the CEO called it another ABBV core area. They have a history of big deals, though reportedly the CEO is tamping down expectations. I guess we'll see if something transpires next year.
  • woodman: $VKTX $GPCR - VKTX flying today as it propels off the 50d. I'm long this. GPCR, keep watch here as it tries to find support at the 50d. I have a smaller position than VKTX in this one. The Obesity drug area is still of interest to big pharma.
  • woodman: @pperlroth $INSM - for sure. You may also like these well performing bios: $CELC $ZBIO $BBIO. Long all of those. Also long $AQST $GPCR and $VKTX, but they are a little stuck right now, and $AXSM. Watching $NKTR (consolidating in a high base) with a placeholder.
  • pperlroth: @woodman $INSM $CELC $ZBIO $BBIO $AQST $GPCR $VKTX $AXSM $NKTR I bought some AQST with the potential approval upcoming. I will look at the others. Been in and out of $BBIO. Got one for. you $ACHV. Fast track for approval potentially for smoking cessation treatment.
  • joelsg1: @woodman $INSM $CELC $ZBIO $BBIO $AQST $GPCR $VKTX $AXSM $NKTR Still holding posted Dec. $125-145 call spreads now filled with 2 weeks to go on $AXSM.
  • bob212: @pperlroth $INSM $CELC $ZBIO $BBIO $AQST $GPCR $VKTX $AXSM $NKTR $ACHV
  • woodman: $XBI $IBB - current bio holdings: $ZBIO $CELC $BBIO $INSM $NKTR (and a small bit of $VKTX and $GPCR). Kicking myself for not buying $VRDN and $AXSM which were on my same shopping list (along with these others) months ago.
  • Motorman: @woodman $XBI $IBB $ZBIO $CELC $BBIO $INSM $NKTR $VKTX $GPCR $VRDN $AXSM IBD wrote a piece on $CELC Nov 10. Did not take a piece, now up 25% in 2 weeks. Missed it. More left in tank?
  • joelsg1: @woodman $XBI $IBB $ZBIO $CELC $BBIO $INSM $NKTR $VKTX $GPCR $VRDN $AXSM Awaiting clinical trial results for $AXSM Alzheimers and depression drugs due this Q-L.
  • woodman: @joelsg1 $XBI $IBB $ZBIO $CELC $BBIO $INSM $NKTR $VKTX $GPCR $VRDN $AXSM - I'm not fond of biotech binary events. Too many scars. Alzheimer's is a tough area, but I'll read up on it.
  • woodman: @Motorman $XBI $IBB $ZBIO $CELC $BBIO $INSM $NKTR $VKTX $GPCR $VRDN $AXSM - I don't think I saw the IBD article, but I bought CELC back right around then. I had it in the $50s, but didn't hang on, unfortunately. Bought it back in the mid $70s.
  • woodman: $VKTX added back previously sold shares today.
  • woodman: ...
    One other thing, GPCR's data could - and I bet will - affect $VKTX share price. These two have competing drugs in trials and are also competing in the acquistion beauty pageant.

  • woodman: $Biotech holding up well. I have several, and only $NKTR is giving me a caution sign. Others (in no particular order) are doing fine: $CELC $INSM $BBIO $ZBIO $GPCR $VKTX
  • woodman: @traderbren $VKTX Good work!
  • Bridgemate: @woodman $VKTX happy happy! wanting more...
  • woodman: Current Biotech positions: $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU. I've been building these up over the last couple months, but not reporting on them because biotech is a minefield and I was reluctant to mention them frequently. But the path has been undeniable for so many bios. I'm not smoking hopium on these, though. I'm in for the charts with a dash of good stories that could keep them going. It is vital, however, to know their catalyst dates or you could get T-boned without seeing it coming. In fact, I am probably in unsafe harbor having this many at once; I need to re-review each of them for the reason stated.
  • kenb: @woodman $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU and adding $ARDX to the list. I'm still holding a large chunk and it's moving up as well from the depths finally.
  • woodman: @kenb $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU $ARDX - I like ARDX as a biotech with a commercialized product serving two indications (IBS with constipation and hyperphosphatemia). My short-intermediate concern is over its appeal on the Xphoza ...
  • joelsg1: @woodman $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU Tailwind for group is rapid changes at FDA, particulary the Center for Drug Development and Research, to emphasize faster and less rigorous drug approvals.
  • woodman: @joelsg1 $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU - Yep, but who the hell knows what's really going on over at FDA and CEDR (Center for Drug Evaluation and Research) now. Cluster F with all the changes in personnel, string-pulling, and whatever guiding priniples there now. Here's some info on the brand new head of CEDR - https://www.fiercepharma.com/pharma/fda-names-longtime-oncology-chief-richard-pazdur-its-new-cder-director
  • joelsg1: @woodman $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU Seems it's pay-to-play over there, in keeping with Administration priorities.
  • woodman: @joelsg1 $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU - And science has taken a back seat.
  • woodman: @Bridgemate $LLY - Very nice, now at ath. $VKTX and $GPCR also with obesity meds in the works on the rise too.
  • Bridgemate: @woodman $LLY $VKTX $GPCR both look good. I drank the koolaid on $VKTX, but it is looking good...
  • woodman: $VKTX flying now.
  • Bridgemate: @woodman $VKTX and I thank you once again!
  • woodman: @Bridgemate $VKTX - glad you pulled the trigger :-)
  • Bridgemate: @woodman $VKTX I did, thanks to you. I will be a better steward this time around... No kool aid for me!
  • woodman: @scottrades $IBB - Big day for biotech. Strong all day, into the close, and even after the close. See $VKTX, e.g.
  • woodman: $VKTX - lots of chatter out there, presentations, good data, and more. Whether buyout is real possibility now or not, it may keep going higher on hype alone. https://ts2.tech/en/viking-therapeutics-vktx-on-nov-11-2025-stifel-fireside-chat-today-fresh-vk2735-obesity-data-from-obesityweek-and-phase-3-vanquish-progress/
  • traderbren: @woodman $VKTX - I've been in Calls once it cleared the 50d and have kept rolling them. It filled the upside gap today, so let's see how it performs from here. Long
  • woodman: $VKTX $GPCR - seeing some interesting chatter in the obesity med area, particularly surrounding the $PFE - $NVO battle to buy Metsera $MTSR. I bought VKTX last week.
  • woodman: $VKTX $GPCR $PFE $NVO $MTSR - Bought some $GPCR.
  • woodman: $VKTX $GPCR $PFE $NVO $MTSR - Re MTSR deal that is brewing - https://www.wsj.com/health/pharma/pfizer-and-metsera-reach-deal-worth-up-to-10-billion-be5def52?st=zjRWqz
  • woodman: $LLY on fire too. $VKTX $GPCR $PFE $NVO $MTSR $LLY
  • joelsg1: @woodman $PFE $NVO $MTSR With $GPCR and $VKTX both with pills waiting in the wings.
  • woodman: @joelsg1 $PFE $NVO $MTSR $GPCR $VKTX - Re VKTX https://www.prnewswire.com/news-releases/viking-therapeutics-highlights-clinical-data-from-vk2735-obesity-program-in-presentation-at-obesityweek-2025-302606589.html
  • joelsg1: @woodman $PFE $NVO $MTSR $GPCR $VKTX Impressive (I think). Anything on their pill?
  • woodman: @joelsg1 $PFE $NVO $MTSR $GPCR $VKTX - Pill completed Phase 2a. I think it has additional data coming this month.
  • woodman: $BBIO #Biotech - back in with a BBIO starter, not big in case it keeps pulling back. I like the story and it was a mistake for me to sell this one back in Sept. I have only 3 biotechs currently: $INSM (held through earnings, so working out well), $NKTR, and BBIO. (I also note $VKTX has been on the move back, but I have no position in it. See $GPCR as well for the obesity med space.) Biotech doing very well. $XBI $IBB
  • traderbren: $VKTX - pushing for a gap close at 40.35. Long from below.
  • woodman: $VKTX - I think buyout *rumors* are moving this stock.
  • Geewhiz: @woodman $VKTX Wish that wasn't in quotes.
  • joelsg1: $GPCR $2 in 1 hour, like @Woodman posted re $VKTX, takeout brewing. Long and finally profitable.
  • woodman: @joelsg1 $GPCR $PFE - $VKTX - also with an oral weight loss candidate - is up as well from the Aug-Sept double bottom following results that were perceived as disappointing, but I don't think is the case, for what little that's worth. (Np in either GPCR or VKTX currently.)
  • traderbren: $VKTX - pushing above the 50d and 200d and working on chewing through the upside gap.
  • rjw225: $GPCR $VKTX -- Just read that 70% of US troops are overweight and that Sec. of War, Hegseth, wants them to be in shape. Maybe this is why $GPCR went up 10% today.
  • woodman: @traderbren - I was away yesterday and this morning. You asked if I am back in $VKTX. I am not.
  • traderbren: $VKTX - getting some interest on the back of the $MTSR deal with $PFE. Hey @Woodman - are you back in $VKTX?
  • woodman: $VKTX continued move in the gap, now teesting the overhead 8dEMA.
  • DavidG: @woodman $LLY $VKTX I like your comment that the oral drugs will be used for maintenance once weight loss is achieved with the parenteral forms. Also no physician who uses these has the high adverse reactions cited in the studies because we presccribe these at lower doses based on tolerance not on some artificial timetable dictated by study design.
  • Lou: @Lou $ET $EPD $MPLX $ALNY $BA $ARDX $FTI $FROG $WELL $SRPT $HUMA $DBRG $CAVA $WLDN Omitted my $VKTX (and short puts) and a relatively small position in $FIG.
  • woodman: $VKTX - added this morning as it enters into the big gap.
  • ReneeH: @woodman $VKTX I kinda like that play. Curious to see if LLY pulls back here at the underside of 50d.
  • woodman: @Henry $LLY - 10.5% weight loss in 72 weeks - a year and a half basically. Eh. $VKTX had 12.5% weight loss for its oral in 13 weeks. Subcutaneous remains the version that provides serious weight loss, though. Moreover, at the end of the day, I think it will come down to which of the drugs patients can tolerate and stay on. If you're throwing up, or can't have a BM, or have diharrea, and these can't be managed significantly, you're not going to stay on the drug for long.
  • woodman: $VKTX - potential gap trade as it tries to move into the gap.
  • shoredriver: @woodman $VKTX ...rearranging itself a smidge higher in the bowl....
  • BocaRick: $VKTX up 8% on volume
  • camaro69: @BocaRick $VKTX moving nice. bought this am. seems over done
  • woodman: @shoredriver $VKTX - I'm trading this gap move with toilet brush in hand.
  • shoredriver: $VKTX....La Merde.....np.....
  • Henry: @shoredriver $VKTX We are so obese, a 12% weight loss is only a rounding error
  • traderbren: @Henry $VKTX - LOL...well said!
  • woodman: @Henry $VKTX - The oral is envisioned as a maintenance drug. It was never envisioned to compete with subcutaneous. 12% is actually at the high end of what analysts were thinking. The issue for all the orals is the tolerability. And what we see here is good efficacy at 12% for an oral, but tolerability that, while manageable does have to be managed. Sounds like titration is a key.
  • woodman: $VKTX - absolute pile-driving today on its oral obesity med data. Funny (not ha ha funny, but rather strange) thing is that detractors are comparing an oral version - which the company has said many times is designed for maintenance after losing one' ...
  • ReneeH: @woodman $VKTX $NVO $LLY it's a love hate here, when they move they move....both directions unfortunately. I feel ya.
  • woodman: @ReneeH $VKTX $NVO $LLY - Trading vs investing, too. You can trade anything generally (though see below for biotech, specifically), but investing is a different thing. I think investing in small/mid cap biotech, particularly with no approved drugs, i ...
  • ReneeH: @woodman $VKTX $NVO $LLY 100% agree, thank you. I'm much more of a trader vs investor. With biotech, I've had a few great hits and a lot of disappointment. Very tricky to time just right.
  • DavidG: @woodman $VKTX Company noted that the placebo group had a high dropout rate because of nausea and vomiting also, so this might make the dropout data look arbitrarily high for the treatment group. On the other hand the chart is the ultimate arbiter.
  • woodman: @DavidG $VKTX - Yeah, that's a bit of a stumper for me. Why such high AE %s for some of those placebos?
  • woodman: $VKTX - this linked write-up https://x.com/hataf_capital/status/1957805522742104543 seems like a pretty balanced review without diving too deeply in any one area of discussion or too deeply into the weeds of the data.

    That said, I think it shoul ...
  • joelsg1: @woodman $VKTX $LLY $NVO $LLY is preparing to flood the zone with their pill even before approval. I think it's a mistake to discount the no-needle convenience of the daily pill, but once massive supply is available, it's pretty much Game Over for the competitors, unless there's a huge difference in tolerability. And even on that last point, millions of people continue to take statins because they see immediate improvement in their cholesterol numbers, despite the fact that for many their feet, ankles, leg muscles hurt.
  • woodman: @joelsg1 $VKTX $LLY $NVO - Funny thing is, I know many on the injectibles, and not one of them complains about it. It's such a nothing burger. At least not from a pain standpoint. But yes swallowing a pill is more convenient than dealing with syringes and vials or even autoinjectors.
  • Bs7518: @woodman $VKTX $LLY $NVO Thanks for sharing the article I take the shot once a week and your right the pain is nothing so the pill is import to me but as an investor it is.
  • woodman: Biotech - I'm long 3: $ARDX $VKTX $SRPT.
    $ARDX - Ibsrela (tenapanor for IBS-C) selling very well and growing. It alone merits a higher share price. Xphozah (tenapanor for hyperphosphatemia) is gravy on top for now, but If Xphozah litigation is resolv ...
  • woodman: $VKTX broke and closed above $40 yesterday. It may waggle some, but as Steven Tyler said, I think this train will keep rolling.
  • woodman: $VKTX $ARDX - my biotech footprint is very light these days. These two are the only ones I have.
  • woodman: $VKTX up again as the breakout/run into coming Phase 2 data (for the oral version of its obesity med) continues. I'm significantly long this one starting from ~$30. I suspect from past practice that the company will announce a date for it to provide ...
  • ReneeH: @woodman $VKTX $LLY fantastic catch last week! watching for a long time, missed it but like it mucho. Thank you.
  • woodman: @ReneeH $VKTX $LLY - Thanks. I started building in early-mid July, so it's been a bit of a wait and see.
  • ReneeH: @woodman $VKTX $LLY tough spot here, but tempting. Data has been positive to date, higher quality than $HIMS, could do something "could" big
  • woodman: @ReneeH $VKTX $LLY $HIMS - And bio, in general, is treacherous.
  • woodman: $VKTX is trying to get through resistance here (horizontal resistance from 2/21 and the 200d). If it can get through, it could have a decent run into phase 2 data for its oral obesity med.
Visit the Trading Forum to join in the discussion.
Stock Price $32.56
Change 0.71%
Volume 1,984,860

Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.

Request Video of VKTX
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!